Meta-analysis of ProGlide versus MANTA vascular closure devices for large-bore access site management
Title
Meta-analysis of ProGlide versus MANTA vascular closure devices for large-bore access site management
Creator
Gauranga Mahalwar
Mariam Shariff
Sanjana Datla
Ankit Agrawal
Sawai Singh Rathore
Taha Bin Arif
Kinza Iqbal
Nabeel Hussain
Monil Majmundar
Ashish Kumar
Ankur Kalra
Date
2022
Description
Introduction: The comparative effectiveness of ProGlide® compared with MANTA® vascular closure devices (VCDs) in large-bore access site management is not entirely certain, and has only been evaluated in underpowered studies. This meta-analysis aimed to evaluate the outcomes of ProGlide® compared with MANTA® VCDs.
Methods: PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched systematically for relevant articles from the inception of the database until August 27, 2021. The outcomes of interest were all bleeding events, major bleeding, major and minor vascular complications, pseudoaneurysm, stenosis or dissection, and VCD failure. Risk ratios were used as point estimates of endpoints. All statistical analyses were carried out using R version 4.0.3.
Results: Four observational studies and 1 pilot randomized controlled trial (RCT) were included in the final analysis. There was no significant difference between the ProGlide® and MANTA® groups in the risk of all bleeding events, major/life-threatening bleeding, major vascular complications, minor vascular complications, pseudoaneurysms, and/or stenosis or dissection of the entry site vessel. However, the incidence of VCD failure was higher in the ProGlide® group compared with the MANTA® group (RR 1.94; 95% CI 1.31-2.84; I2 = 0%).
Conclusion: In conclusion, both VCDs (ProGlide® and MANTA®) have comparable outcomes with regard to risk of bleeding, vascular complications, pseudoaneurysms, and/or stenosis or dissection of entry vessel. ProGlide® was however associated with higher device failure.
Methods: PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched systematically for relevant articles from the inception of the database until August 27, 2021. The outcomes of interest were all bleeding events, major bleeding, major and minor vascular complications, pseudoaneurysm, stenosis or dissection, and VCD failure. Risk ratios were used as point estimates of endpoints. All statistical analyses were carried out using R version 4.0.3.
Results: Four observational studies and 1 pilot randomized controlled trial (RCT) were included in the final analysis. There was no significant difference between the ProGlide® and MANTA® groups in the risk of all bleeding events, major/life-threatening bleeding, major vascular complications, minor vascular complications, pseudoaneurysms, and/or stenosis or dissection of the entry site vessel. However, the incidence of VCD failure was higher in the ProGlide® group compared with the MANTA® group (RR 1.94; 95% CI 1.31-2.84; I2 = 0%).
Conclusion: In conclusion, both VCDs (ProGlide® and MANTA®) have comparable outcomes with regard to risk of bleeding, vascular complications, pseudoaneurysms, and/or stenosis or dissection of entry vessel. ProGlide® was however associated with higher device failure.
Source
Indian Heart J
. 2022 May-Jun;74(3):251-255. doi: 10.1016/j.ihj.2022.03.003. Epub 2022 Mar 31.
. 2022 May-Jun;74(3):251-255. doi: 10.1016/j.ihj.2022.03.003. Epub 2022 Mar 31.
Language
English
URL
https://doi.org/10.1016/j.ihj.2022.03.003
Citation
Gauranga Mahalwar et al., “Meta-analysis of ProGlide versus MANTA vascular closure devices for large-bore access site management,” NEOMED Bibliography Database, accessed May 10, 2024, https://neomed.omeka.net/items/show/12146.